PLK1 inhibitors synergistically potentiate HDAC inhibitor lethality in IM -sensitive or – resistant BCR/ABL(+) leukemia cells in vitro and in vivo

PURPOSE: To determine whether PLK1 inhibitors (e.g. BI2536) and HDAC inhibitor (e.g. vorinostat) interact synergistically in CML cells sensitive or resistant to imatinib mesylate (IM) in vitro and in vivo. EXPERIMENTAL DESIGN: K562 and LAMA84 cells sensitive or resistant to IM and primary CML cells...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Dasmahapatra, Girija, Patel, Hiral, Nguyen, Tri, Attkisson, Elisa, Grant, Steven
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2012
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC3548959/
https://ncbi.nlm.nih.gov/pubmed/23204129
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-12-2799
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk